BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 18973931)

  • 1. Absence of MGMT promoter methylation in endometrial cancer.
    Rimel BJ; Huettner P; Powell MA; Mutch DG; Goodfellow PJ
    Gynecol Oncol; 2009 Jan; 112(1):224-8. PubMed ID: 18973931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.
    Paz MF; Yaya-Tur R; Rojas-Marcos I; Reynes G; Pollan M; Aguirre-Cruz L; García-Lopez JL; Piquer J; Safont MJ; Balaña C; Sanchez-Cespedes M; García-Villanueva M; Arribas L; Esteller M
    Clin Cancer Res; 2004 Aug; 10(15):4933-8. PubMed ID: 15297393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Detection of O6-methylguanine-DNA methyltransferase promoter methylation in chemotherapy for glioma].
    Zheng CQ; Ji SP; Gong F; Li AM; Tai JL; Zhang YP
    Ai Zheng; 2009 Jun; 28(6):575-80. PubMed ID: 19635193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia.
    Esteller M; Hamilton SR; Burger PC; Baylin SB; Herman JG
    Cancer Res; 1999 Feb; 59(4):793-7. PubMed ID: 10029064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas.
    Brell M; Tortosa A; Verger E; Gil JM; Viñolas N; Villá S; Acebes JJ; Caral L; Pujol T; Ferrer I; Ribalta T; Graus F
    Clin Cancer Res; 2005 Jul; 11(14):5167-74. PubMed ID: 16033832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.
    Pyko IV; Nakada M; Sabit H; Teng L; Furuyama N; Hayashi Y; Kawakami K; Minamoto T; Fedulau AS; Hamada J
    Carcinogenesis; 2013 Oct; 34(10):2206-17. PubMed ID: 23715499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylation of O-6-methylguanine DNA methyltransferase characterizes a subset of colorectal cancer with low-level DNA microsatellite instability.
    Whitehall VL; Walsh MD; Young J; Leggett BA; Jass JR
    Cancer Res; 2001 Feb; 61(3):827-30. PubMed ID: 11221863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. O6-methylguanine-DNA methyltransferase gene: epigenetic silencing and prognostic value in head and neck squamous cell carcinoma.
    Zuo C; Ai L; Ratliff P; Suen JY; Hanna E; Brent TP; Fan CY
    Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):967-75. PubMed ID: 15184253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer.
    Ogino S; Hazra A; Tranah GJ; Kirkner GJ; Kawasaki T; Nosho K; Ohnishi M; Suemoto Y; Meyerhardt JA; Hunter DJ; Fuchs CS
    Carcinogenesis; 2007 Sep; 28(9):1985-90. PubMed ID: 17621591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
    Hochhauser D; Glynne-Jones R; Potter V; Grávalos C; Doyle TJ; Pathiraja K; Zhang Q; Zhang L; Sausville EA
    Mol Cancer Ther; 2013 May; 12(5):809-18. PubMed ID: 23443801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MGMT promoter methylation and field defect in sporadic colorectal cancer.
    Shen L; Kondo Y; Rosner GL; Xiao L; Hernandez NS; Vilaythong J; Houlihan PS; Krouse RS; Prasad AR; Einspahr JG; Buckmeier J; Alberts DS; Hamilton SR; Issa JP
    J Natl Cancer Inst; 2005 Sep; 97(18):1330-8. PubMed ID: 16174854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisulfite profiling of the MGMT promoter and comparison with routine testing in glioblastoma diagnostics.
    Tierling S; Jürgens-Wemheuer WM; Leismann A; Becker-Kettern J; Scherer M; Wrede A; Breuskin D; Urbschat S; Sippl C; Oertel J; Schulz-Schaeffer WJ; Walter J
    Clin Epigenetics; 2022 Feb; 14(1):26. PubMed ID: 35180887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant methylation and loss of expression of O-methylguanine-DNA methyltransferase in pulmonary squamous cell carcinoma and adenocarcinoma.
    Furonaka O; Takeshima Y; Awaya H; Kushitani K; Kohno N; Inai K
    Pathol Int; 2005 Jun; 55(6):303-9. PubMed ID: 15943786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A specific CpG methylation pattern of the MGMT promoter region associated with reduced MGMT expression in primary colorectal cancers.
    Herfarth KK; Brent TP; Danam RP; Remack JS; Kodner IJ; Wells SA; Goodfellow PJ
    Mol Carcinog; 1999 Feb; 24(2):90-8. PubMed ID: 10078936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivation of DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation and its relation to p53 mutations in esophageal squamous cell carcinoma.
    Zhang L; Lu W; Miao X; Xing D; Tan W; Lin D
    Carcinogenesis; 2003 Jun; 24(6):1039-44. PubMed ID: 12807758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The high frequency of de novo promoter methylation in synchronous primary endometrial and ovarian carcinomas.
    Furlan D; Carnevali I; Marcomini B; Cerutti R; Dainese E; Capella C; Riva C
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3329-36. PubMed ID: 16740754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis.
    Esteller M; Risques RA; Toyota M; Capella G; Moreno V; Peinado MA; Baylin SB; Herman JG
    Cancer Res; 2001 Jun; 61(12):4689-92. PubMed ID: 11406538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07.
    Schraml P; von Teichman A; Mihic-Probst D; Simcock M; Ochsenbein A; Dummer R; Michielin O; Seifert B; Schläppi M; Moch H; von Moos R
    Oncol Rep; 2012 Aug; 28(2):654-8. PubMed ID: 22614944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylation of the O6-methylguanine-DNA methyltransferase promoter suppresses expression in mouse skin tumors and varies with the tumor induction protocol.
    Abdel-Fattah R; Glick A; Rehman I; Maiberger P; Hennings H
    Int J Cancer; 2006 Feb; 118(3):527-31. PubMed ID: 16094607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. O(6)-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: enzyme activity, promoter methylation and immunohistochemistry.
    Christmann M; Verbeek B; Roos WP; Kaina B
    Biochim Biophys Acta; 2011 Dec; 1816(2):179-90. PubMed ID: 21745538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.